We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+56.7%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$347M
AUM Growth
+$107M
Cap. Flow
+$4.3M
Cap. Flow %
1.24%
Top 10 Hldgs %
48.52%
Holding
95
New
16
Increased
11
Reduced
34
Closed
8

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$7.34M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$6.6M
3
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$6.16M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.48M
5
LQDA icon
Liquidia Corp
LQDA
+$4.17M

Top Sells

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$4.64M
2
DXCM icon
DexCom
DXCM
+$4.37M
3
CRBP icon
Corbus Pharmaceuticals
CRBP
+$4.31M
4
CGEN icon
Compugen
CGEN
+$3.47M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.68M

Sector Composition

Rank Sector Weight
1 Healthcare 88.26%
2 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
26
Liquidia Corp
LQDA
$7.86B
$4.63M 1.34%
+550,000
New +$4.17M
XENE icon
27
Xenon Pharmaceuticals
XENE
$6.19B
$4.35M 1.25%
346,535
– –
AERI
28
DELISTED
Aerie Pharmaceuticals
AERI
$4.13M 1.19%
279,440
-14,000
-5% -$207K
AFMD
29
DELISTED
Affimed
AFMD
$3.9M 1.13%
84,500
-28,840
-25% -$803K
BCRX icon
30
BioCryst Pharmaceuticals
BCRX
$2.29B
$3.54M 1.02%
744,051
+265,000
+55% +$1.06M
ALEC icon
31
Alector
ALEC
$171M
$3.42M 0.99%
140,000
-15,000
-10% -$414K
VKTX icon
32
Viking Therapeutics
VKTX
$3.84B
$3.25M 0.94%
450,900
– –
SIOX
33
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.83M 0.82%
1,005,391
-16,175
-2% -$51.9K
KDMN
34
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.83M 0.82%
553,564
-3,000
-0.5% -$13.4K
BEAT
35
DELISTED
BioTelemetry, Inc.
BEAT
$2.73M 0.79%
60,500
– –
KALV
36
DELISTED
KalVista Pharmaceuticals
KALV
$2.69M 0.78%
222,452
-12,500
-5% -$133K
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.5M 0.72%
21,893
-20,209
-48% -$1.96M
ASND icon
38
Ascendis Pharma A/S
ASND
$16B
$2.11M 0.61%
14,237
-19,500
-58% -$2.68M
BLUE
39
DELISTED
bluebird bio
BLUE
$1.85M 0.53%
2,337
+368
+19% +$278K
ISEE
40
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.82M 0.53%
+357,500
New +$1.49M
RCUS icon
41
Arcus Biosciences
RCUS
$3.62B
$1.78M 0.51%
72,100
+44,302
+159% +$1.2M
OTIC
42
DELISTED
Otonomy, Inc.
OTIC
$1.7M 0.49%
469,135
– –
LRMR icon
43
Larimar Therapeutics
LRMR
$427M
$1.62M 0.47%
126,261
+100,803
+396% +$1.17M
TPTX
44
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$1.5M 0.43%
23,210
-23,698
-51% -$1.37M
PHAS
45
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$1.47M 0.43%
320,542
– –
HARP
46
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.41M 0.41%
8,512
-6,235
-42% -$973K
ZGNX
47
DELISTED
Zogenix, Inc.
ZGNX
$1.37M 0.4%
50,749
-92,500
-65% -$2.55M
ARAY icon
48
Accuray
ARAY
$37.2M
$1.37M 0.4%
674,300
– –
JNJ icon
49
Johnson & Johnson
JNJ
$614B
$1.32M 0.38%
9,400
– –
ARDX icon
50
Ardelyx
ARDX
$1.24B
$1.28M 0.37%
184,850
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, DAFNA Capital Management held 95 positions worth $347M, up 45% from $240M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management's Q2 2020 filing shows 16 new, 11 increased, 34 reduced and 8 closed positions. Its largest new stake was Immunomedics Inc: 250,905 shares worth $8.89M. The largest sale was AtriCure, an estimated $4.64M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 92% a quarter earlier, followed by Financials.

  • DAFNA Capital Management's largest Q2 2020 buy was Immunomedics Inc: 250,905 shares worth $8.89M.
  • DAFNA Capital Management added most to Dicerna Pharmaceuticals, Inc. in Q2 2020, an estimated $6.6M increase.
  • DAFNA Capital Management's biggest Q2 2020 reduction was AtriCure, cutting an estimated $4.64M.
  • DAFNA Capital Management fully exited Epizyme, Inc in Q2 2020, selling an estimated $1.64M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $347M portfolio in Q2 2020.
  • DAFNA Capital Management opened 16 new positions and closed 8 in Q2 2020.
  • DAFNA Capital Management's portfolio value rose 45% quarter-over-quarter to $347M.

Based on DAFNA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.